LONDON, UK / ACCESSWIRE / January 23, 2018 / Active-Investors.com has just released a free research report on Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) ("Tonix"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TNXP as the Company's latest news hit the wire. On January 19, 2018, the Company, which is an organization developing innovative pharmaceutical and biological products to address major public health challenges and diseases with significant unmet needs, announced the publication of a research outlining the successful synthesis and characterization of a potential smallpox-preventing vaccine based on horsepox virus. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Tonix Pharmaceuticals Holding most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=TNXP
About the Research Publication
Tonix conducted this research in collaboration with scientists from the University of Alberta, a leading Canadian research university. The peer-reviewed article, ‘Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments', was published in the PLOS ONE journal. This came after Tonix's announcement of the complete synthesis of the horsepox virus using synthetic biology technology in March 2017. As per the research and development agreement, Tonix wholly owns the synthesized horsepox virus stock and related sequences.
Relation between Horsepox and Smallpox
Horsepox, which is an equine disease caused by the horsepox virus, is believed to have become extinct through some natural process. In fact, no horsepox outbreaks have been reported since 1976, at which time the US Department of Agriculture got the viral sample used for the sequence published in 2006, which is the basis for TNX-801. English physician and scientist, Dr. Edward Jenner, speculated in 1798 that a vaccine derived from cowpox could protect humans against smallpox. Jenner believes that this vaccine that he isolated from what was known as cowpox in cows, began as a pox disease in horses. And thus, smallpox was eradicated as a result of Jenner's vaccine.
Tonix is Developing a Synthetic Version of Horsepox Virus as a Potential Vaccine for Smallpox
Tonix is creating a synthetic version of the horsepox virus from cell culture, titled TNX-801, as a potential vaccine for preventing smallpox infection in humans. TNX-801 is a live form of horsepox virus (HPXV) that has proven to have protective vaccine activity in mice. At present, TNX-801 is in its pre-Investigational New Drug (IND) application stage. Evolutionary evidence shows that the vaccines that eradicated smallpox in the US and Europe in the 19th century were closely related to horsepox.
Seth Lederman, M.D., President and Chief Executive Officer (CEO) at Tonix, shared that, currently, smallpox vaccines are used to safeguard first responders and military service members in the Army's Global Response Force who face increased risks of smallpox outbreak. However, due to their toxicity and harmful side effects, the vaccines are not used for immunizing the whole at-risk population. Instead, they are stockpiled in the US Strategic National Stockpile. Therefore, Tonix looks forward to developing an improved smallpox preventing vaccine that has a better safety profile and is more appropriate for broader usage.
An Initiative in Public Interest
Professor David Evans, Ph.D., FCAHS, Professor and Vice-Dean (Research), Faculty of Medicine and Dentistry at the University of Alberta, in Edmonton, Alberta, Canada, and principal investigator of the TNX-801 research project believes that this research will facilitate informed discussions about potential applications of synthetic biology for improving public health, encouraging new evaluation of horsepox-based vaccines, and developing the manufacturing process to rapidly produce next-generation vaccines and therapeutics.
José Esparza, M.D., Ph.D., former President of the Global Virus Network, former Senior Advisor on Global Health (Vaccines) to the Bill and Melinda Gates Foundation, and currently adjunct professor at the Institute of Human Virology at the University of Maryland School of Medicine, also had similar views. He has not been personally involved in the research but he believes that an improved smallpox vaccine would address the well-recognized risk of the intentional re-introduction of the smallpox virus. He feels that ignoring the risk of smallpox intentional re-introduction, or depending on current vaccines that have limitations, would not be in the best interest of the public.
Professor Evans and Research Associate, Ryan Noyce, Ph.D., at the University of Alberta, synthesized Horsepox with Dr. Lederman as co-investigator of the research and co-inventor of TNX-801.
Stock Performance Snapshot
January 22, 2018 - At Monday's closing bell, Tonix Pharmaceuticals Holding's stock advanced 6.04%, ending the trading session at $4.04.
Volume traded for the day: 144.88 thousand shares, which was above the 3-month average volume of 72.46 thousand shares.
Stock performance in the last month – up 16.43%; and year-to-date - up 17.10%
After yesterday's close, Tonix Pharmaceuticals Holding's market cap was at $30.42 million.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 0.9% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
